Niagen Bioscience, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $64.8M | $44.5M | $27.2M | $20.3M | $28.2M | $16.7M | $18.8M | $22.6M |
| Accounts Receivable | $9.7M | $7.8M | — | $8.5M | $5.2M | $2.7M | $2.2M | $4.4M |
| Inventory | — | $9.2M | $14.5M | $14.7M | $13.6M | $11.7M | $11.5M | $8.2M |
| Total Current Assets | $96.8M | $64.1M | $49.5M | $46.6M | $48.9M | $32.2M | $33.5M | $36.5M |
| Property, Plant & Equipment | — | — | — | — | — | $3.2M | $3.8M | $3.6M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $5.7M | $359.0K | $510.0K | $671.0K | $857.0K | $1.1M | $1.3M | $1.5M |
| Total Assets | $106.4M | $68.3M | $55.0M | $54.1M | $57.8M | $38.4M | $40.2M | $42.2M |
| Liabilities | ||||||||
| Accounts Payable | $10.8M | $8.5M | $10.2M | $9.7M | $10.4M | $9.4M | $9.6M | $9.5M |
| Total Current Liabilities | $19.9M | $17.9M | $20.6M | $17.9M | $17.6M | $16.5M | $15.1M | $14.4M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $29.9M | $22.2M | $26.5M | $25.4M | $26.1M | $21.9M | $19.8M | $15.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-164.5M | $-181.9M | $-190.5M | $-185.5M | $-169.0M | $-141.8M | $-121.9M | $-89.8M |
| Total Stockholders' Equity | $76.5M | $46.1M | $28.5M | $28.7M | $31.7M | $16.4M | $20.4M | $27.2M |